A widespread economic problem of RSV vaccine candidates is their inefficient production. RSV vaccine candidates are produced in Vero, a cell line isolated from African green monkey kidney. Infectious disease experts at Nationwide Children’s Hospital have discovered RSV grown in Vero cells has a cleaved, non-functional attachment glycoprotein (G protein). Our experts identified mutations in the G protein that prevent its cleavage during production in the Vero cell line. Importantly, these mutations increase RSV vaccine production efficiency up to 10 times, making vaccine production now economically feasible.